NovaGray’s mission is to personalize treatment for patients with breast and prostate cancer.
The innovations developed by NovaGray aim to:
- Reassure patients in preparation for radiotherapy
- Guide physicians in choosing the most appropriate treatment plan
- Adapt patient follow-up after radiotherapy
CLEMENCE FRANC (CHIEF EXECUTIVE OFFICER, CO-FOUNDER)
Clemence holds an engineering degree from ESTP Paris and an entrepreneurship degree from HEC Paris. Specializing in the development of innovative technologies, she is in charge of all strategic and financial aspects of the company’s development. Clemence was named as Top 10 French Innovator Under 35 by MIT Technological Review in 2017.
DAVID AZRIA, M.D., Ph.D (CHIEF MEDICAL OFFICER, CO-FOUNDER)
David Azria is professor in radiation oncology at the School of Medicine of Montpellier and has a PhD in radiobiology. He is the head of the radiation oncology Department of the Montpellier Cancer Institute (ICM) and the INSERM team U1194, and is a lead contributor in many French and international institutional clinical trials. David has more than 220 publications referenced in PubMed. He received the Translational Science Abstract Award at the American Society for Radiation Oncology (ASTRO) Annual Meeting in October 2015. Since 2022, David is President of the French Society of Radiation Oncology (SFRO).
MURIEL BRENGUES, Ph.D (CHIEF SCIENTIFIC OFFICER)
Muriel Brengues is an expert in ionizing radiation. She has a PhD in Biochemistry, Molecular and Cellular Biology, a Master in Biology and Health, and a Bachelor Degree in Biochemistry. She currently works in David Azria ́s research team, and previously worked for 10 years in the USA, at the Applied NanoBioscience Center and Medicine Department and the Molecular and Cellular Department of the University of Arizona. Before moving to the USA, she was a researcher at the National Center for Scientific Research (CNRS) in France for 6 years.